Clinic
Community Memorial Hospital of Menomonee Falls INC
Community Memorial Hospital of Menomonee Falls INC was paid $10.09M by Medicaid between Jan 2018 and Dec 2024, across 243 billing codes. Its largest line is 99283, emergency room visit (moderate) — 16% of everything it billed.
33Billing provider infoCOMMUNITY MEMORIAL HOSPITAL OF MENOMONEE FALLS INC
MENOMONEE FALLS, WI 53051
MENOMONEE FALLS, WI 53051
33aNPI1609822881assigned 05/26/2006
33bProvider typeAdult Mental Health Clinic/Center
28Total paid$10.09M
24GClaims577,626
24DCodes billed243
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Adult Mental Health Clinic/Center providers in Wisconsin
Rank by total paid#1 of 15
Median peer was paid$169K
This provider vs. median60×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 68,106 | $1.30M | |
| 2019 | 77,439 | $1.40M | |
| 2020 | 78,292 | $1.39M | |
| 2021 | 82,993 | $1.43M | |
| 2022 | 88,090 | $1.42M | |
| 2023 | 102,210 | $1.68M | |
| 2024incomplete | 80,496 | $1.48M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 16% | 28,973 | 25,255 | $1.58M |
| 96361 | Intravenous infusion, hydration; each additional hour | 14% | 13,016 | 9,679 | $1.40M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 10% | 20,971 | 17,953 | $1.03M |
| 80053 | Comprehensive metabolic panel | 5.0% | 19,706 | 15,630 | $505K |
| 80048 | Basic metabolic panel (calcium, ionized) | 4.2% | 22,965 | 16,902 | $423K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 3.6% | 5,393 | 4,773 | $361K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 3.1% | 6,357 | 4,103 | $316K |
| 70450 | Computed tomography, head or brain; without contrast material | 3.1% | 5,570 | 4,951 | $315K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 2.4% | 4,079 | 3,430 | $244K |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | 2.1% | 3,245 | 2,848 | $213K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | 2.1% | 3,275 | 1,620 | $211K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | 1.8% | 1,818 | 1,658 | $177K |
231 more codes
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 1.7% | 3,936 | $176K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.7% | 33,590 | $176K |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | 1.5% | 2,650 | $152K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | 1.4% | 4,811 | $145K |
| 71275 | Computed tomographic angiography, chest, with contrast material | 1.4% | 1,902 | $139K |
| G0378 | Hospital observation service, per hour | 1.3% | 5,839 | $127K |
| 84484 | 1.0% | 14,154 | $101K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 3,296 | $94K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 3,303 | $88K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 1,584 | $86K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 4,887 | $85K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 1,417 | $84K |
| 81025 | <1% | 9,250 | $78K | |
| 99285 | Emergency room visit (most serious) | <1% | 1,875 | $77K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 6,228 | $63K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 679 | $56K |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 856 | $56K |
| 83880 | <1% | 2,743 | $51K | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 1,402 | $50K |
| 85610 | <1% | 6,058 | $49K | |
| 83690 | <1% | 9,210 | $48K | |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 1,169 | $45K |
| 81001 | <1% | 12,416 | $43K | |
| 82962 | <1% | 8,408 | $43K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 870 | $42K |
| 83735 | <1% | 9,763 | $40K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 1,883 | $39K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 4,952 | $37K |
| 87077 | <1% | 3,078 | $34K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 1,714 | $32K |
| 85027 | <1% | 6,790 | $30K | |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 569 | $29K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 786 | $29K |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 1,234 | $28K |
| C8929 | Transthoracic echocardiography with contrast, or without contrast followed by with contrast, real-time with image documentation (2d), includes m-mode recording, when performed, complete, with spectral doppler echocardiography, and with color flow doppler echocardiography | <1% | 391 | $28K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 2,830 | $28K |
| 96367 | <1% | 546 | $27K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 946 | $26K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 2,973 | $25K |
| 84702 | <1% | 1,648 | $24K | |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 214 | $23K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 2,041 | $23K |
| 97162 | <1% | 1,167 | $22K | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 953 | $22K |
| 80076 | <1% | 3,838 | $22K | |
| 85379 | <1% | 2,939 | $21K | |
| 83605 | <1% | 2,631 | $20K | |
| 93971 | <1% | 884 | $19K | |
| 87210 | <1% | 2,756 | $19K | |
| 80143 | <1% | 1,362 | $18K | |
| 76830 | Ultrasound, transvaginal | <1% | 717 | $18K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 3,247 | $18K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 1,223 | $17K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 320 | $17K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 217 | $16K |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 363 | $16K |
| 82077 | <1% | 1,553 | $15K | |
| 87081 | <1% | 1,138 | $15K | |
| 87088 | <1% | 2,436 | $14K | |
| 87040 | <1% | 2,441 | $14K | |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 108 | $13K |
| 80179 | <1% | 1,327 | $13K | |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 75 | $13K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 324 | $13K |
| 87186 | <1% | 2,327 | $13K | |
| 97116 | <1% | 1,790 | $11K | |
| 80061 | Lipid panel | <1% | 1,091 | $11K |
| 82728 | <1% | 964 | $10K | |
| 82805 | <1% | 465 | $10K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 15,383 | $9K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 5,933 | $9K |
| 87275 | <1% | 373 | $9K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 9,273 | $9K |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 1,709 | $9K |
| 97161 | <1% | 422 | $9K | |
| 82607 | <1% | 575 | $9K | |
| 86850 | <1% | 1,061 | $8K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 18,227 | $7K |
| 76642 | <1% | 209 | $7K | |
| 84100 | <1% | 2,690 | $6K | |
| 70496 | <1% | 67 | $6K | |
| 81003 | <1% | 2,432 | $6K | |
| 71045 | Radiologic examination, chest; single view | <1% | 8,629 | $5K |
| 85730 | <1% | 1,381 | $5K | |
| 70498 | <1% | 54 | $5K | |
| 80050 | General health panel | <1% | 746 | $5K |
| 87276 | <1% | 373 | $5K | |
| 82550 | <1% | 1,090 | $4K | |
| 86140 | <1% | 1,086 | $4K | |
| 97166 | <1% | 416 | $4K | |
| 86900 | <1% | 1,788 | $4K | |
| 87070 | <1% | 385 | $4K | |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 69 | $4K |
| 83615 | <1% | 1,128 | $3K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 512 | $3K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 10,999 | $3K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 52 | $3K |
| 93976 | <1% | 102 | $3K | |
| 84439 | <1% | 379 | $3K | |
| 86901 | <1% | 1,279 | $3K | |
| 93017 | <1% | 130 | $3K | |
| 12001 | <1% | 26 | $2K | |
| 97165 | <1% | 131 | $2K | |
| 71250 | <1% | 88 | $2K | |
| 82565 | <1% | 133 | $2K | |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | <1% | 437 | $2K |
| 76801 | <1% | 374 | $2K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 66 | $2K |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 30 | $2K |
| 73630 | <1% | 815 | $2K | |
| 72131 | <1% | 75 | $2K | |
| 84550 | <1% | 818 | $2K | |
| 74183 | <1% | 16 | $2K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 9,469 | $2K |
| 70486 | <1% | 61 | $2K | |
| 82150 | <1% | 54 | $2K | |
| 96376 | <1% | 4,581 | $1K | |
| 73560 | <1% | 1,681 | $1K | |
| 83550 | <1% | 254 | $1K | |
| 90715 | <1% | 209 | $1K | |
| 84703 | <1% | 146 | $1K | |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 20 | $1K |
| 77065 | Tomosynthesis, mammo | <1% | 169 | $1K |
| 83540 | <1% | 263 | $1K | |
| 77061 | <1% | 71 | $1K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 353 | $785.50 |
| 87205 | <1% | 346 | $753.47 | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 28 | $724.34 |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 25 | $683.67 |
| 36415 | Collection of venous blood by venipuncture | <1% | 9,424 | $669.14 |
| 36591 | <1% | 1,260 | $662.49 | |
| 85007 | <1% | 386 | $625.74 | |
| 73610 | <1% | 594 | $617.61 | |
| 84145 | <1% | 38 | $567.67 | |
| 82950 | <1% | 176 | $537.97 | |
| Q3014 | Telehealth originating site facility fee | <1% | 100 | $498.49 |
| G0103 | Prostate cancer screening; prostate specific antigen test (psa) | <1% | 30 | $438.99 |
| 72128 | <1% | 15 | $434.41 | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 14 | $431.08 |
| 83970 | <1% | 14 | $429.04 | |
| 90686 | <1% | 42 | $425.12 | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 4,968 | $419.00 |
| 82570 | <1% | 86 | $390.89 | |
| 36000 | <1% | 313 | $386.30 | |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 13 | $332.63 |
| 85652 | <1% | 198 | $330.49 | |
| 73030 | <1% | 718 | $325.61 | |
| 86592 | <1% | 15 | $322.74 | |
| 82746 | <1% | 26 | $316.77 | |
| J0134 | Injection, acetaminophen (fresenius kabi), not therapeutically equivalent to j0131, 10 mg | <1% | 204 | $316.14 |
| 85045 | <1% | 87 | $279.11 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 11,675 | $277.14 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 10,598 | $252.53 |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 28 | $238.05 |
| 84156 | <1% | 67 | $222.93 | |
| 87075 | <1% | 51 | $217.34 | |
| 73130 | <1% | 317 | $212.97 | |
| 36416 | <1% | 4,842 | $171.83 | |
| 82330 | <1% | 13 | $162.71 | |
| G0008 | Administration of influenza virus vaccine | <1% | 181 | $158.15 |
| 73502 | <1% | 216 | $150.49 | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 2,909 | $135.07 |
| 80164 | <1% | 15 | $127.07 | |
| 88342 | <1% | 26 | $123.40 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 6,873 | $121.28 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 3,329 | $102.31 |
| 82947 | <1% | 35 | $99.99 | |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 1,658 | $98.85 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 2,783 | $95.34 |
| 74018 | <1% | 148 | $79.04 | |
| 73110 | <1% | 56 | $73.22 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 2,876 | $60.21 |
| 88304 | <1% | 33 | $52.62 | |
| 72100 | <1% | 29 | $52.45 | |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 445 | $51.43 |
| 73090 | <1% | 20 | $38.36 | |
| J2704 | Injection, propofol, 10 mg | <1% | 4,782 | $35.64 |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 3,068 | $28.21 |
| P9612 | Catheterization for collection of specimen, single patient, all places of service | <1% | 350 | $27.45 |
| J2060 | Injection, lorazepam, 2 mg | <1% | 1,376 | $22.98 |
| A9585 | Injection, gadobutrol, 0.1 ml | <1% | 1,895 | $22.59 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 1,683 | $20.32 |
| 85018 | <1% | 19 | $12.49 | |
| 85014 | <1% | 20 | $12.49 | |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 638 | $9.48 |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 3,725 | $8.74 |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 44 | $8.32 |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 283 | $7.30 |
| Q9956 | Injection, octafluoropropane microspheres, per ml | <1% | 641 | $7.14 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 5,006 | $4.79 |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 1,829 | $4.59 |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 1,559 | $4.39 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 4,842 | $2.36 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 34 | $2.03 |
| J1790 | Injection, droperidol, up to 5 mg | <1% | 575 | $1.09 |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 308 | $0.83 |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 1,635 | $0.65 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 2,258 | $0.65 |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | <1% | 1,245 | $0.03 |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | 0% | 136 | $0.00 |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | 0% | 429 | $0.00 |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | 0% | 371 | $0.00 |
| J0360 | Injection, hydralazine hcl, up to 20 mg | 0% | 144 | $0.00 |
| 51798 | 0% | 14 | $0.00 | |
| C1769 | Guide wire | 0% | 91 | $0.00 |
| J1630 | Injection, haloperidol, up to 5 mg | 0% | 14 | $0.00 |
| J8540 | Dexamethasone, oral, 0.25 mg | 0% | 65 | $0.00 |
| J1940 | Injection, furosemide, up to 20 mg | 0% | 118 | $0.00 |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | 0% | 19 | $0.00 |
| J2371 | Injection, phenylephrine hydrochloride, 20 micrograms | 0% | 388 | $0.00 |
| J2785 | Injection, regadenoson, 0.1 mg | 0% | 58 | $0.00 |
| J3411 | Injection, thiamine hcl, 100 mg | 0% | 57 | $0.00 |
| J0500 | Injection, dicyclomine hcl, up to 20 mg | 0% | 15 | $0.00 |
| J8501 | Aprepitant, oral, 5 mg | 0% | 14 | $0.00 |
| 72170 | 0% | 27 | $0.00 | |
| G8987 | Self care functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 16 | $0.00 |
| Q9969 | Tc-99m from non-highly enriched uranium source, full cost recovery add-on, per study dose | 0% | 17 | $0.00 |
| 0352U | 0% | 15 | $0.00 | |
| G8988 | Self care functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 16 | $0.00 |
| C1776 | Joint device (implantable) | 0% | 125 | $0.00 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | 0% | 170 | $0.00 |
| 51702 | 0% | 13 | $0.00 | |
| J1171 | Injection, hydromorphone, 0.1 mg | 0% | 95 | $0.00 |
| A9502 | Technetium tc-99m tetrofosmin, diagnostic, per study dose | 0% | 109 | $0.00 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | 0% | 584 | $0.00 |
| C1887 | Catheter, guiding (may include infusion/perfusion capability) | 0% | 33 | $0.00 |
| Q9957 | Injection, perflutren lipid microspheres, per ml | 0% | 13 | $0.00 |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 0% | 28 | $0.00 |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 15 | $0.00 |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 35 | $0.00 |
| 73590 | 0% | 17 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialLUX, TERESA (PRESIDENT)
| Provider | Location | Paid |
|---|---|---|
| Community Memorial Hospital of Menomonee Falls, INC | Menomonee Falls, WI | $190K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.